School of Medicine
Showing 61-70 of 106 Results
-
Amalia Perna
Postdoctoral Scholar, Pathology
BioDr. Perna received her education at the University of Urbino (BSc in Biological Science) and at the University of Trieste (MSc in Functional Genomics).
She obtained her Ph.D. in Neuroscience/Medical Sciences in 2021, from the University of Fribourg (Switzerland) in collaboration with the Swiss Integrative Center for Human Health (SICHH). During her doctoral studies, she investigated the molecular players involved in the neurodegenerative process, with special attention to Notch signaling modulation in the neuronal demise after kainic acid (KA)-induced excitotoxicity
With funding from the Swiss National Science Foundation (SNSF), Dr. Perna joined Prof. Thomas Montine's lab at Stanford University and extended her doctoral research work to single-cell technologies such as single-nucleus RNA-seq. In February 2022 she was appointed as a postdoctoral fellow in Montine Lab.
Dr. Perna’s research aims to elucidate the modulation of signaling pathways in the different cell types of the brain after the perturbation of its homeostasis. She is also interested in understanding the molecular mechanisms underlying neuronal regeneration/recovery after damage and in neurodegenerative diseases. -
Suman Rimal
Postdoctoral Scholar, Pathology
BioResearch interests: Genetic mechanism underlying mitochondrial pathology, neurodegeneration, and muscle loss using Drosophila as a model organism.
-
Matteo Santoro Pharm.D., Ph.D.
Postdoctoral Scholar, Pathology
BioDr. Santoro joined Shamloo’s lab in March 2021 focusing his research on Parkinson’s disease, neuronal vulnerability, and identification of therapeutic markers in relation to α-synucleinopathies. Prior to his arrival at Stanford, he held a position as a clinical monitor at Syneos Health where he gained key knowledge needed to translate lab-based findings into clinical and commercial applications. Previously, Dr. Santoro held a postdoctoral position at the University of Aberdeen (Scotland, UK) working on amyloid-beta extracts from Alzheimer’s disease patients. During his postdoctoral research, Dr. Santoro designed and optimized a cost-effective and rapid assay for the measurement of toxic amyloid-beta species in human biofluids. In 2017, he obtained his Ph.D. (4-year program) at the University of Aberdeen on Parkinson’s disease (PD), immunology, and behavior. The major findings Ph.D. findings were the following: 1) the characterization of a small protein called HMGB1 as an inflammatory mediator in PD; 2) the motor and non-motor behavioral characterization of three neurotoxin based mouse models of PD, 3) the characterization of the innate immune response in PD through the toll-like receptor signaling pathways 4) evaluation of the effects of chronic systemic inflammation on both resident and infiltrating immune cells in the CNS. In 2012 Dr. Santoro attained his Pharm.D. in chemistry and pharmaceutical technology (5-year program) at the University of Calabria (Italy) during which he undertook an internship at the King’s College London (SGDP Centre) and worked for over a year on a rat model of stroke.
